Attached files
file | filename |
---|---|
8-K - CURRENT REPORT - MYMETICS CORP | mymx_8k.htm |
Exhibit
99.1
Press Release
Anergis
and Mymetics Start Research Collaboration Project on the use of
Virosomes for Ultra-Fast Allergy Immunotherapy
Epalinges, Switzerland, April 23, 2018 – Mymetics
Corporation (OTCQB:MYMX), a pioneer and leader in the research and
development of virosome-based vaccines, and Anergis SA, a company
developing Contiguous Overlapping Peptides (COPs) for ultra-fast
allergy immunotherapy, announced today that Mymetics SA, the Swiss
subsidiary of Mymetics Corporation and Anergis SA have entered into
a Research Collaboration project.
The
pre-clinical study program will evaluate the immunogenicity profile
of the Anergis peptides designed to treat birch allergy (the Bet v1
COPs) when presented on Mymetics’ proprietary virosomes, with
or without undisclosed TLR ligands or other adjuvants, and will
compare the results to Anergis’ AllerT product combination
(Bet v1 COPs with aluminum hydroxide).
The
research collaboration will start now and the results are expected
by Q1 2019. If this project is successful, Anergis will have the
option to enter into an exclusive license agreement for the use of
virosomes in allergy.
“We
are very excited to start this initial research project with
Anergis, a leading company in ultra-fast allergy
immunotherapy” said Ronald Kempers, CEO of Mymetics.
“We look forward to show that our proprietary virosome
technology and vaccine expertise can make a valuable difference in
improving the effectiveness of treating
allergies.”
“On
the basis of the extensive clinical experience available with
virosomes and with Anergis COPs against birch allergy, we are
convinced that their combination represents a highly attractive
opportunity to develop safe and efficacious ultra-fast COP allergy
vaccines” commented Vincent Charlon, CEO of
Anergis.
About Mymetics
Mymetics
Corporation (OTCQB:MYMX) is a Swiss based biotechnology company,
with a research lab in the Netherlands, focused on the development
of next-generation preventative vaccines for infectious and life
disabling diseases. It currently has five vaccines in its pipeline:
HIV-1/AIDS, intra-nasal Influenza, Malaria, Chikungunya, Herpes
Simplex Virus and the RSV vaccine. HIV, malaria and intra-nasal
influenza vaccines have successfully finished Phase 1 clinical
trials, while the others are in the pre-clinical
phase.
Mymetics’
core technology and expertise are in the use of virosomes,
lipid-based carriers containing functional fusion viral proteins
and natural membrane proteins, in combination with rationally
designed antigens. Mymetics’ vaccines are designed to induce
protection against early transmission and infection, focusing on
the mucosal immune response as a first-line defense, in combination
with humoral and cellular immune responses as a second-line
defense, which can be essential for the development of an effective
vaccine.
For
further information, please visit www.mymetics.com.
About Anergis
Anergis
SA is a Swiss biopharmaceutical company dedicated to the discovery
and development of novel, ultra-fast, proprietary allergy
immunotherapy products for the most prevalent allergies. Anergis
core technology is based on Contiguous Overlapping Peptides (COP)
which together contain the full amino acid sequence of one or more
major allergens ; COP do not bind the pre-existing IgE of allergic
patients and can therefore be administered at higher doses than
allergens without the risk of immediate allergic reactions. Anergis
completed three clinical Phase II trials with its product candidate
against birch pollen allergies, AllerT, containing Bet v1 COPs and
aluminium hydroxide as an adjuvant. Two additional COP product
candidates against ragweed pollen (Amb a1 COPs) and house dust mite
(Der p COPs) allergies are in preclinical development. Anergis has
raised over CHF 52 million from private and institutional
investors, including BioMedInvest, Renaissance PME, Sunstone
Capital, and WJFS, Inc.
1
About Allergies
Allergies
are the most prevalent and fastest growing chronic conditions in
the industrialized world, affecting over 500 million people. The
only curative therapy of allergies available today, known as
“desensitization”, “allergy shots” or
“Conventional Allergy Immunotherapy” (AIT), is the
process of inducing tolerance to the allergen by administering the
allergen itself to patients. AIT requires three to five years of
treatment and exposes patients to the risk of serious side effects
such as immediate anaphylactic reactions. With its technology,
Anergis is shaping the future of allergy treatment by developing
therapeutic modalities that only require two months of
treatment.
CONTACTS:
Mymetics
Corporation
Ronald
Kempers
Chief
Executive Officer
Tel:
+41 21 653 4535
info@mymetics.com
Anergis SA
Vincent
Charlon
Chief
Executive Officer
info@anergis.ch
Forward looking statements
The
Private Securities Litigation Reform Act of 1995 provides a "safe
harbor" for forward-looking statements, which are identified by the
words "believe," "expect," "anticipate," "intend," "plan" and
similar expressions. The statements contained herein which are not
based on historical facts are forward-looking statements that
involve known and unknown risks and uncertainties that could
significantly affect our actual results, performance or
achievements in the future and, accordingly, such actual results,
performance or achievements may materially differ from those
expressed or implied in any forward-looking statements made by or
on our behalf. These risks and uncertainties include, but are not
limited to, risks associated with our ability to successfully
develop and protect our intellectual property, our ability to raise
additional capital to fund future operations and compliance with
applicable laws and changes in such laws and the administration of
such laws. See Mymetics' most recent Form 10-K for a discussion of
such risks, uncertainties and other factors. Readers are cautioned
not to place undue reliance on these forward- looking statements
which speak only as of the date the statements were
made.
2